News >

Single-Agent and Combo Approvals Lead to Personalized Approach in RCC

Ellie Leick
Published: Monday, Jan 06, 2020

Ajjai Shivaram Alva, MBBS, an associate professor at the University of Michigan

Ajjai Shivaram Alva, MBBS

The approval of several TKIs and combination regimens has led to more treatment options for patients with renal cell carcinoma (RCC), with a heavier focus on individualized approaches, explained Ajjai Shivaram Alva, MBBS.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication